Abbott Laboratories (NYSE:ABT) Chairman and CEO Robert B. Ford disclosed a personal purchase of company common stock on January 23, 2026, according to a Form 4 filing with the Securities and Exchange Commission. Ford acquired 18,800 shares at a reported per-share price of $107.1259, bringing the total value of the transaction to $2,013,966.
The filing notes the execution price for the shares traded in a range between $106.735 and $107.485. After the purchase, Ford's direct holdings in Abbott amount to 253,305 shares. In addition, he holds 216,203 shares indirectly via the Ford Family Trust.
Analyst reactions after Q4 2025
The purchase comes as Abbott faces several analyst reassessments following its fourth-quarter 2025 results. The company reported 3.8% organic sales growth in the quarter, excluding COVID-related revenue, a figure described in filings as lower than expectations. That performance and the company's 2026 organic sales guidance have prompted a range of responses from sell-side firms.
- UBS has sustained its Buy rating and set a $158 price target while noting investor concerns about Abbott's 2026 organic sales guidance.
- Bernstein SocGen Group reduced its price target to $125, attributing the move to a "surprise Q4 sales miss" and a slowdown in the continuous glucose monitoring business.
- TD Cowen trimmed its price target to $137, citing a revenue miss and more cautious sales guidance for 2026.
- Benchmark reaffirmed its Buy rating with a $145 price target, calling out weakness in the Nutrition Products segment.
- RBC Capital lowered its price target to $135, highlighting missed revenue expectations across all segments.
These revisions illustrate varied perspectives among analysts on Abbott's near-term trajectory following the quarter's results.
Context and disclosure
The Form 4 disclosure provides a snapshot of insider purchasing activity and immediate stock ownership following the transaction. The analyst updates cited above reflect post-quarter reactions from multiple firms and note both specific segment weakness and overall revenue shortfalls reported by Abbott in the fourth quarter of 2025.
No additional claims or forward-looking assertions are made beyond the details presented in the filing and the analyst notes referenced.